Cancer Management:A Multidisciplinary ApproachMedical, Surgical & Radiation OncologyContributors to Cancer Management: Contributors to Cancer Management:A Multidisciplinary ApproachMedical, Surgical & Radiation Oncology
Contributors Thomas E. Ahlering, MD
Dennis S. Chi, MD
Steven R. Alberts, MD
Warren Chow, MD
Penny R. Anderson, MD
Lawrence R. Coia, MD
Kathleen W. Beekman, MD
Jay S. Cooper, MD
Al B. Benson III, MD
Jorge E. Cortes, MD
J. Sybil Biermann, MD
Jeffrey Crawford, MD
Charles D. Blanke, MD
Carey A. Cullinane, MD
Eduardo Bruera, MD
Lisa M. DeAngelis, MD
Mark Buyyounouski, MD
Lawrence Driver, MD
Emiliano Calvo, MD, PhD
Joshua D. I. Ellenhorn, MD
Carmen P. Escalante, MD
Steven M. Grunberg, MD
Andrew M. Evens, DO
Bruce G. Haffty, MD
Gilbert G. Fareau, MD
John Hoffman, MD
Paul Fisher, MD
Brent K. Hollenbeck, MD
Stephen J. Forman, MD
Eric M. Horwitz, MD
Michael J. Gazda, MS
William J. Hoskins, MD
Bonnie S. Glisson, MD
Mark Hurwitz, MD
Leo I. Gordon, MD
Maha Hussain, MD
Frederic W. Grannis, Jr., MD
Jimmy J. Hwang, MD
Kathryn M. Greven, MD
James Ito, Jr., MD
Rajesh V. Iyer, MD
Jeffrey P. Lamont, MD
Sundar Jagannath, MD
Rachelle M. Lanciano, MD
Ishmael Jaiyesimi, DO
Miriam N. Lango, MD
Lori Jardines, MD
Joseph Lattanzi, MD
Aminah Jatoi, MD
Alan List, MD
Eric H. Jensen, MD
Jay S. Loeffler, MD
Hagop Kantarjian, MD
Patrick J. Loehrer, MD
John J. Kavanagh, MD
Charles Loprinzi, MD
Kemp H. Kernstine, MD, PhD
Robert Lustig, MD
Fadlo R. Khuri, MD
Robert Maki, MD, PhD
Lily Lai, MD
Adam N. Mamelak, MD
Nicole Lamanna, MD
Gary N. Mann, MD
Ellen Manzullo, MD
Bert O’Neil, MD
Kim A. Margolin, MD
I. Benjamin Paz, MD
Maurie Markman, MD
Richard Pazdur, MD
David Scott Miller, MD
Carlos A. Perez, MD
Ronald T. Mitsuyasu, MD
Louis L. Pisters, MD
Judd W. Moul, MD
Peter W. T. Pisters, MD
Benjamin Movsas, MD
Stephen P. Povoski, MD
Nikhil C. Munshi, MD
Bruce G. Redman, DO
Robert J. Myerson, MD, PhD
Paul Richardson, MD
Nicos Nicolaou, MD
John Andrew Ridge, MD, PhD
Margaret R. O’Donnell, MD
John M. Robertson, MD
Steven T. Rosen, MD
David Straus, MD
Melanie Royce, MD, PhD
Chris H. Takimoto, MD, PhD
Stephen C. Rubin, MD
Alan Valentine, MD
Paul Sabbatini, MD
Rena Vassilopoulou-Sellin, MD
Roderich E. Schwarz, MD, PhD
Lawrence D. Wagman, MD
Walter Scott, MD
Sharon M. Weinstein, MD
Marisa Siebel, MD
Lawrence M. Weiss, MD
Richard T. Silver, MD
Mark A. Weiss, MD
Douglas Skarecky, BS
Mitchell Weiss, MD
Vernon K. Sondak, MD
Jeffrey Weitzel, MD
William G. Wierda, MD, PhD
Alan W. Yasko, MD
Jane N. Winter, MD
Sriram Yennurajalingam, MD
Joachim Yahalom, MD
Sally Yowell Barbour, PHARMD
Cara H. Glynn
Sr. Editorial Director
Angela Cibuls
Project Manager
Susan Reckling
Managing Editor
Stacey Cuozzo
Production Editor
Terri Gelfand
Sr. Editorial Coordinator
Lisa Katz
Creative Director
Jeannine Coronna
Publishing Operations Director
Melissa Warner
Group Vice President/General Manager
Newsletter Stay up to date on recent advances in the multidisciplinary approach to cancer.
Subscribe
October 19th, 2026 Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
October 19th, 2026 “Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
October 19th, 2026 Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
October 19th, 2026 Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
October 19th, 2026 The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
October 19th, 2026 Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
October 19th, 2026 The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
October 19th, 2026 Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.